Neurotune Successfully Completes Phase 1 Trials with its Lead Compound NT-11624
SCHLIEREN, Switzerland, January 15, 2009--Neurotune AG, a Swiss biopharmaceutical company, which has recently acquired two programs in neuropathic pain, announces the successful completion of Phase I for its lead compound NT-11624 developed for treatment of neuropathic and ostheoarthritic pain.
NT-11624, dimiracetam, is a selective small molecular NMDA-receptor antagonist, which acts on a new site of the receptor. The studies on 56 healthy volunteers performed in Switzerland have demonstrated excellent tolerability of the compound both by subjective reports and objective physical, instrumental and laboratory tests with favorable kinetics and no clinically relevant food effects on the molecule kinetics.
"We have reached an important step in the development of our Company" said Andreas J. Schulze PhD, Neurotune's CEO "as we are preparing for the submission of the regulatory approval of a phase II study in South Africa on pain caused by retroviral treatment induced peripheral neuropathy in HIV patients". "The data obtained" - added Ruggero G. Fariello MD, Neurotune's CMO - "are such to allow us to move confidently into clinical pathologies to explore efficacy of our product in a wide range of doses, giving us the confidence of an optimal tolerability profile within that range".
Mrs. Nadia De Marinis
Assistant to the CEO
Wagistrasse 27 a
Phone +41 44 200 21 95
Fax +41 44 200 21 80
Dr. Holger Bengs
Phone +49 69 6199 4273
Fax +49 69 6199 4249
About Neurotune AG
Neurotune was incorporated in January 2005 and has its domicile in Schlieren, Switzerland. Neurotune develops small-molecular drugs to treat disorders of the human nervous system.
About Neuropathic Pain
Neuropathic pain is a type of chronic pain. It is a result of damage to the nervous system following infection, disease, injury, and certain medications. Neuropathic pain serves no protective function. Instead of functioning properly to warn of tissue injury, the nervous system malfunctions and becomes the cause of the pain. Neuropathic pain can continue for months or years and is often described as "burning," "electric," "tingling," or "shooting."
This press release contains forward-looking statements. Neurotune disclaims any intent or obligation to update these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected size and timing of closing of the registered direct offering. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in meeting closing conditions, and actions of regulatory authorities relating to the Neurotune's shelf registration statement and the registered direct offering. For further information regarding these and other risks related to Neurotune's business, investors should consult Neurotune.
Posted: January 2009